Soy isoflavones for viral chest infections in infants
Part of Lungs & breathing clinical trials.
This study tests whether giving a soy-based supplement to infants with a viral chest infection can reduce wheezing and other symptoms. It aims to see if this natural compound helps the immune system fight the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be 4 to 24 months old and born at full term (at least 37 weeks).
- Your baby must have a viral chest infection that started within the last 1–3 days.
- Your baby must be able to take the supplement mixed in food or liquid (like breast milk or formula).
- Your baby must not be on a soy-based formula already.
- Your baby must not have a known allergy to soy.
- Your baby must not have certain thyroid or genetic conditions.
- You must be willing to let staff do nasal swabs and answer questionnaires.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether daily soy isoflavones can lower the chance of asthma or wheezing problems in babies who are at high risk. You would join because your baby has risk factors (family history and certain genetics) and receives the study soy product.
This study tests if giving oral steroids (medicine to reduce airway swelling) only when needed based on a child's own biology can help preschool children with wheezing. It aims to find the best treatment for each child, avoiding unnecessary medicine.
This study tests a medicine called a bacterial lysate, which might help prevent respiratory infections and wheezing in babies born early. It could reduce sickness and breathing problems in the first year of life.
This study uses video recordings to see how well salbutamol helps children with wheezing caused by a virus. Researchers want to understand when this medicine works best.
This trial tests whether a nebulized (inhaled mist) steroid medicine called fluticasone propionate helps reduce wheezing in infants under 2 years old. It aims to see if this treatment is safe and effective for babies who are hospitalized with wheezing.
This trial tests whether a medication can prevent wheezing after a baby's first chest infection, especially for those with risk factors. It may help reduce future breathing problems.
Hear when a new Wheezing trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.